A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine

This clinical trial will enroll 160 participants who previously took part in the Phase I clinical trial of the adsorbed acellular pentavalent (five-component) DTP-polio combination vaccine (for individuals aged 6 years and older) (Protocol No.: CTP-Tdcp-001). Approximately 3-4 mL of venous blood will be collected from each participant 2.5 years, 5 years, and 10 years after vaccination for a study on immune persistence.

NCT Number	NCT07744347
Lead Sponsor	CanSino Biologics Inc.
Conditions	Diphtheria, Tetanus, Pertussis
Enrollment	160 participants
Start Date	2026-10-15
Primary Completion	2033-10-15 (estimated)
Study Completion	2033-10-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-04